A number of recent studies suggest that one of the reasons that tumors do not provoke protective immune responses in the host is that tumors do not induce effective """"""""help"""""""" for the generation of cytotoxic T lymphocytes (CTL). The basis for this failure may be that tumors lack the signals necessary for activation of T cells. It has been demonstrated that T cells require two signals for activation, an antigen-specific signal generated via the antigen receptor, and a second costimulatory signal. Without the second signal, Tcells not only fail to respond, but enter a long-lived stated of antigen-specific anergy. Recent studies have strongly implicated the T cell surface molecule CD28 as the costimulatory receptor, and the B7 molecule as its ligand on the antigen presenting cell. Expression of the costimulatory ligand is largely restricted to B cells, macrophages, and dendritic cells. Many solid tumors appear to lack B7 expression and thus may have a poor capacity to directly activate T cell responses and may even induce specific non-responsiveness. We propose a novel approach to immunotherapy which will exploit the costimulatory receptor and its ligand to enhance the immunogenicity of tumors in a mouse model. A monoclonal antibody to the costimulatory receptor CD28 will be used to provide costimulation systemically, and the gene for the costimulatory ligand B7 will be used to provide costimulation specifically by the tumor. The effectiveness of the antibody and gene therapy approaches in preventing the growth of primary tumors, established tumors, and in eliciting immunity to subsequent tumor challenge will be assessed in vivo. The mechanism of protection will be determined by analyzing helper and killer T cells in treated mice. We will also determine whether the costimulatory approach can be used in the long term propagation of tumor specific T cells in vitro for use in adoptive immunotherapy and the identification of tumor-specific antigens. Since reagents are currently available for the human costimulatory receptor and ligand, the results of this study can be rapidly transferred to treatment of human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057986-03
Application #
2098691
Study Section
AIDS and Related Research Study Section 4 (ARRD)
Project Start
1992-08-20
Project End
1997-05-31
Budget Start
1994-08-01
Budget End
1995-05-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of California Berkeley
Department
Internal Medicine/Medicine
Type
Schools of Arts and Sciences
DUNS #
094878337
City
Berkeley
State
CA
Country
United States
Zip Code
94704
Zhang, Meili; Ju, Wei; Yao, Zhengsheng et al. (2012) Augmented IL-15R? expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol 188:6156-64
Curran, Michael A; Allison, James P (2009) Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 69:7747-55
Egen, Jackson G; Kuhns, Michael S; Allison, James P (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-8
van Elsas, A; Sutmuller, R P; Hurwitz, A A et al. (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481-9
van Elsas, A; Hurwitz, A A; Allison, J P (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied J Exp Med 190:355-66
Hurwitz, A A; Townsend, S E; Yu, T F et al. (1998) Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 77:107-13
Kwon, E D; Hurwitz, A A; Foster, B A et al. (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 94:8099-103
Leach, D R; Krummel, M F; Allison, J P (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-6
Chambers, C A; Krummel, M F; Boitel, B et al. (1996) The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27-46
Townsend, S E; Su, F W; Atherton, J M et al. (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54:6477-83

Showing the most recent 10 out of 11 publications